Patents by Inventor Mingsong WEI

Mingsong WEI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12188814
    Abstract: The present application provides a method, apparatus, and electronic device for detecting ambient light under a display screen, which could reduce the influence of a light leak from a screen on detection of the ambient light. The method includes: generating an interval identification signal for screen light of the display screen according to a dimming period of the display screen, the interval identification signal being used to identify the screen light that is within a specific time interval in the dimming period; performing data collection according to a sampling signal; reading data of a target sampling period from data of a plurality of sampling periods of the sampling signal according to the interval identification signal, the target sampling period being a sampling period in which sampling time overlaps with the specific time interval in time; and detecting the ambient light according to the data of the target sampling period.
    Type: Grant
    Filed: December 12, 2022
    Date of Patent: January 7, 2025
    Assignee: SHENZHEN GOODIX TECHNOLOGY CO., LTD.
    Inventors: Mingsong Wei, Xiangyu Yang, Luming Zhou
  • Publication number: 20230204413
    Abstract: The present application provides a method, apparatus, and electronic device for detecting ambient light under a display screen, which could reduce the influence of a light leak from a screen on detection of the ambient light. The method includes: generating an interval identification signal for screen light of the display screen according to a dimming period of the display screen, the interval identification signal being used to identify the screen light that is within a specific time interval in the dimming period; performing data collection according to a sampling signal; reading data of a target sampling period from data of a plurality of sampling periods of the sampling signal according to the interval identification signal, the target sampling period being a sampling period in which sampling time overlaps with the specific time interval in time; and detecting the ambient light according to the data of the target sampling period.
    Type: Application
    Filed: December 12, 2022
    Publication date: June 29, 2023
    Applicant: SHENZHEN GOODIX TECHNOLOGY CO., LTD.
    Inventors: Mingsong WEI, Xiangyu YANG, Luming ZHOU
  • Patent number: 10428081
    Abstract: Epidermal growth factor receptor (EGFR) inhibitors are provided. In particular, 4-substituted-2-(N-(5-substituted ally amide)phenyl)amino)pyrimidine derivatives of formula (I), a preparation method and use thereof as an EGFR inhibitor are provided. The 4-substituted-2-(N-(5-substituted ally amide)phenyl)amino)pyrimidine derivatives of formula (I) have inhibitory activity against the L858R EGFR mutant, the T790M EGFR mutant and the exon 19 deletion activating mutant, and can be used to treat diseases mediated alone or in part by EGFR mutant activity. The derivatives of formula (I) can be used to treat and/or prevent cancers, particularly non-small cell lung cancer.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: October 1, 2019
    Assignees: SHANGHAI HANSOH BIOMEDICAL CO., LTD., JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Mingsong Wei, Guangjun Sun, Songliang Tan, Peng Gao, Shaobao Wang, Wenhua Xiu, Fujun Zhang, Rudi Bao
  • Patent number: 10259820
    Abstract: Epidermal growth factor receptor (EGFR) inhibitors are provided. In particular, 4-substituted-2-(N-(5-substituted allyl amide)phenyl)amino)pyrimidine derivatives of formula (I), a preparation method and use thereof as an EGFR inhibitor are provided. The 4-substituted-2-(N-(5-substituted allyl amide)phenyl)amino)pyrimidine derivatives of formula (I) have inhibitory activity against the L858R EGFR mutant, the T790M EGFR mutant and the exon 19 deletion activating mutant, and can be used to treat diseases mediated alone or in part by EGFR mutant activity. The derivatives of formula (I) can be used to treat and/or prevent cancers, particularly non-small cell lung cancer.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: April 16, 2019
    Assignees: SHANGHAI HANSOH BIOMEDICAL CO., LTD., JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Mingsong Wei, Guangjun Sun, Songliang Tan, Peng Gao, Shaobao Wang, Wenhua Xiu, Fujun Zhang, Rudi Bao
  • Publication number: 20190100528
    Abstract: Epidermal growth factor receptor (EGFR) inhibitors are provided. In particular, 4-substituted-2-(N-(5-substituted ally amide)phenyl)amino)pyrimidine derivatives of formula (I), a preparation method and use thereof as an EGFR inhibitor are provided. The 4-substituted-2-(N-(5-substituted ally amide)phenyl)amino)pyrimidine derivatives of formula (I) have inhibitory activity against the L858R EGFR mutant, the T790M EGFR mutant and the exon 19 deletion activating mutant, and can be used to treat diseases mediated alone or in part by EGFR mutant activity. The derivatives of formula (I) can be used to treat and/or prevent cancers, particularly non-small cell lung cancer.
    Type: Application
    Filed: December 3, 2018
    Publication date: April 4, 2019
    Inventors: Mingsong WEI, Guangjun SUN, Songliang TAN, Peng GAO, Shaobao WANG, Wenhua XIU, Fujun ZHANG, Rudi BAO
  • Publication number: 20170313714
    Abstract: Epidermal growth factor receptor (EGFR) inhibitors are provided. In particular, 4-substituted-2-(N-(5-substituted allyl amide)phenyl)amino)pyrimidine derivatives of formula (I), a preparation method and use thereof as an EGFR inhibitor are provided. The 4-substituted-2-(N-(5-substituted allyl amide)phenyl)amino)pyrimidine derivatives of formula (I) have inhibitory activity against the L858R EGFR mutant, the T790M EGFR mutant and the exon 19 deletion activating mutant, and can be used to treat diseases mediated alone or in part by EGFR mutant activity. The derivatives of formula (I) can be used to treat and/or prevent cancers, particularly non-small cell lung cancer.
    Type: Application
    Filed: September 30, 2015
    Publication date: November 2, 2017
    Applicants: Shanghai Hansoh Biomedical Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    Inventors: Mingsong WEI, Guangjun SUN, Songliang TAN, Peng GAO, Shaobao WANG, Wenhua XIU, Fujun ZHANG, Rudi BAO